GlassScriptPhysician profile
Phaedra M Dowell
NPI 1437411725
$3,278.38
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,407 · 2020: $852 · 2024: $19.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $19.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $19.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $365.78 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $216.98 | 2019-2020 | |
| Ucb, INC. | $214.87 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $201.53 | 2019-2020 | |
| Acorda Therapeutics, INC | $190.81 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $147.42 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $145.17 | 2019-2020 | |
| Emd Serono, INC. | $135.55 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $122.06 | 2019-2020 | |
| Abbvie INC. | $121.83 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $118.34 | 2019 | |
| Amgen INC. | $114.60 | 2019-2020 | |
| Genzyme Corporation | $98.28 | 2019-2020 | |
| Lilly USA, LLC | $93.88 | 2019-2020 | |
| Medtronic USA, INC. | $74.48 | 2019 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $72.11 | 2019-2020 | |
| Allergan, INC. | $60.45 | 2019-2020 | |
| Aquestive Therapeutics, INC. | $55.17 | 2019 | |
| Grt US Holding, INC. | $50.92 | 2020 | |
| Upsher-Smith Laboratories LLC | $47.63 | 2019-2020 | |
| Kyowa Kirin, INC. | $46.16 | 2019-2020 | |
| Promius Pharma LLC | $42.18 | 2019 | |
| Adamas Pharmaceuticals, INC. | $41.91 | 2019-2020 | |
| Mdd US Operations, LLC | $41.85 | 2020 | |
| Sunovion Pharmaceuticals INC. | $41.30 | 2019 | |
| Zyla Life Sciences, INC. | $38.68 | 2019-2020 | |
| Greenwich Biosciences, INC. | $38.19 | 2019 | |
| Genentech USA, INC. | $34.97 | 2019-2020 | |
| Abbott Laboratories | $33.02 | 2020 | |
| Livanova USA, INC. | $29.21 | 2019 | |
| Lundbeck LLC | $29.08 | 2019-2020 | |
| Eisai INC. | $26.31 | 2019 | |
| Csl Behring | $25.75 | 2019 | |
| Assertio Therapeutics, INC. | $25.65 | 2019-2020 | |
| Ge Healthcare | $25.21 | 2019 | |
| Arbor Pharmaceuticals, INC. | $25.12 | 2019-2020 | |
| Boston Scientific Corporation | $25.00 | 2019 | |
| Medtronic, INC. | $19.97 | 2024 | Percept PC Brainsense |
| Grifols USA, LLC | $19.26 | 2019 | |
| Mallinckrodt Enterprises LLC | $11.88 | 2019 | |
| Travere Therapeutics, INC. | $9.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phaedra Dowell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.